<?xml version='1.0' encoding='utf-8'?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-us"><title>Docket updates for IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://michaellee50.github.io/CourtListener/feed-MDL-No.-3094.xml" rel="self" type="application/atom+xml" /><link href="https://www.courtlistener.com/" rel="alternate" /><link href="https://www.courtlistener.com/docket/68082231/feed/" rel="self" /><id>https://www.courtlistener.com/</id><updated>2025-12-03T00:00:00-08:00</updated><author><name>Free Law Project</name><email>feeds@courtlistener.com</email></author><rights>Created for the public domain by Free Law Project</rights><entry><title>Entry #377 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-377" rel="alternate" /><published>2025-12-03T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-377</id><summary type="html">***TEXT ONLY NOTICE******A PROOF OF SERVICE IS REQUIRED FOR ALL FILINGS***NOTICE OF FILING OF CTO AND PUBLICATION OF BRIEFING SCHEDULE (CTO-45) re: pldg. ( 376 in MDL No. 3094, 1 in NJ/3:25-cv-17963, 1 in NJ/3:25-cv-17967, 1 in NJ/3:25-cv-17971, 1 in NJ/3:25-cv-17974, 1 in NJ/3:25-cv-18064, 1 in NJ/3:25-cv-18075, 1 in NJ/3:25-cv-18076) BRIEFING SCHEDULE IS SET AS FOLLOWS: Oppositions due on or before 12/10/2025.Attorneys must be registered to file in the JPML. Please visit our website for Registration Information. Signed by Clerk of the Panel James V. Ingold on 12/3/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17963, NJ/3:25-cv-17967, NJ/3:25-cv-17971, NJ/3:25-cv-17974, NJ/3:25-cv-18064, NJ/3:25-cv-18075, NJ/3:25-cv-18076 (CT) (Entered: 12/03/2025)</summary><link href="https://ecf.jpml.uscourts.gov/cgi-bin/show_case_doc?377,1674416,,," length="0" rel="enclosure" /><updated>2025-12-03T00:00:00-08:00</updated></entry><entry><title>Entry #376 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-376" rel="alternate" /><published>2025-12-03T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-376</id><summary type="html">CONDITIONAL TRANSFER ORDER FILED TODAY (CTO-45) - 7 action(s) Signed by Clerk of the Panel James V. Ingold on 12/3/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17963, NJ/3:25-cv-17967, NJ/3:25-cv-17971, NJ/3:25-cv-17974, NJ/3:25-cv-18064, NJ/3:25-cv-18075, NJ/3:25-cv-18076 (CT) (Entered: 12/03/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001524278?caseid=1674416" length="0" rel="enclosure" /><updated>2025-12-03T00:00:00-08:00</updated></entry><entry><title>Entry #375 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-375" rel="alternate" /><published>2025-12-02T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-375</id><summary type="html">DOCUMENT (AMENDED) - Filed by Plaintiff Burnice Davis Associated Cases: MDL No. 3094, ALM/1:25-cv-00739 (McGowan, Stephen) (Entered: 12/02/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001524236?caseid=1674416" length="0" rel="enclosure" /><updated>2025-12-02T00:00:00-08:00</updated></entry><entry><title>Entry #374 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-374" rel="alternate" /><published>2025-12-02T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-374</id><summary type="html">NOTICE OF POTENTIAL TAG-ALONG -- 2 Action(s) -- Filed by attorney Diana M. Watral, P.C., counsel for Defendants Eli Lilly and Company and Lilly USA, LLC -- New Jersey District Court (2:25-cv-18075,2:25-cv-18076) (Attachments: # 1 Schedule of Actions, # 2 Proof of Service, # 3 Complaint- DNJ 2:25-cv-18075, # 4 Complaint- DNJ 2:25-cv-18076) (Watral, Diana) (Entered: 12/02/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001524066?caseid=1674416" length="0" rel="enclosure" /><updated>2025-12-02T00:00:00-08:00</updated></entry><entry><title>Entry #373 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-373" rel="alternate" /><published>2025-12-02T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-373</id><summary type="html">CONDITIONAL TRANSFER ORDER FINALIZED (CTO-43) - 3 action(s) re: pldg. (1 in INS/1:25-cv-02376, 1 in KYW/3:25-cv-00733, 366 in MDL No. 3094, 1 in NJ/3:25-cv-17639) Inasmuch as no objection is pending at this time, the stay is lifted. Signed by Clerk of the Panel James V. Ingold on 12/2/2025. Associated Cases: MDL No. 3094, INS/1:25-cv-02376, KYW/3:25-cv-00733, NJ/3:25-cv-17639 (CT) (Entered: 12/02/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001524009?caseid=1674416" length="0" rel="enclosure" /><updated>2025-12-02T00:00:00-08:00</updated></entry><entry><title>Entry #372 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-372" rel="alternate" /><published>2025-12-01T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-372</id><summary type="html">NOTICE OF POTENTIAL TAG-ALONG -- 1 Action(s) -- Filed by attorney Diana M. Watral, P.C., counsel for Defendants Eli Lilly and Company and Lilly USA, LLC -- New Jersey District Court (3:25-cv-18064) (Attachments: # 1 Schedule of Actions, # 2 Proof of Service, # 3 Complaint - 3:25-cv-18064) (Watral, Diana) (Entered: 12/01/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001523972?caseid=1674416" length="0" rel="enclosure" /><updated>2025-12-01T00:00:00-08:00</updated></entry><entry><title>Entry #371 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-371" rel="alternate" /><published>2025-11-26T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-371</id><summary type="html">NOTICE OF POTENTIAL TAG-ALONG -- 4 Action(s) -- Filed by attorney Diana M. Watra, counsel for Defendants Eli Lilly and Company and Lilly USA, LLC -- New Jersey District Court (3:25-cv-17967,3:25-cv-17963,3:25-cv-17971,3:25-cv-17974) (Attachments: # 1 Schedule of Actions, # 2 Proof of Service, # 3 Complaint 3:25-cv-17963, # 4 Complaint 3:25-cv-17967, # 5 Complaint 3:25-cv-17971, # 6 Complaint 3:25-cv-17974) (Watral, Diana) Modified on 12/1/2025 (CT). ADDED PARTY TYPE. Modified on 12/1/2025 (CT). (Entered: 11/26/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001523717?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-26T00:00:00-08:00</updated></entry><entry><title>Entry #370 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-370" rel="alternate" /><published>2025-11-26T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-370</id><summary type="html">***TEXT ONLY NOTICE******A PROOF OF SERVICE IS REQUIRED FOR ALL FILINGS***NOTICE OF FILING OF CTO AND PUBLICATION OF BRIEFING SCHEDULE (CTO-44) re: pldg. ( 369 in MDL No. 3094, 1 in NJ/3:25-cv-17893) BRIEFING SCHEDULE IS SET AS FOLLOWS: Oppositions due on or before 12/3/2025.Attorneys must be registered to file in the JPML. Please visit our website for Registration Information. Signed by Clerk of the Panel James V. Ingold on 11/26/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17893 (CT) (Entered: 11/26/2025)</summary><link href="https://ecf.jpml.uscourts.gov/cgi-bin/show_case_doc?370,1674416,,," length="0" rel="enclosure" /><updated>2025-11-26T00:00:00-08:00</updated></entry><entry><title>Entry #369 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-369" rel="alternate" /><published>2025-11-26T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-369</id><summary type="html">CONDITIONAL TRANSFER ORDER FILED TODAY (CTO-44) - 1 action(s) Signed by Clerk of the Panel James V. Ingold on 11/26/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17893 (CT) (Entered: 11/26/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001523552?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-26T00:00:00-08:00</updated></entry><entry><title>Entry #368 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-368" rel="alternate" /><published>2025-11-24T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-368</id><summary type="html">NOTICE OF POTENTIAL TAG-ALONG -- 1 Action(s) -- Filed by attorney Diana M. Watral, P.C., counsel for Defendants Eli Lilly and Company and Lilly USA, LLC -- New Jersey District Court (2:25-cv-17893) (Attachments: # 1 Schedule of Actions, # 2 Proof of Service, # 3 Complaint- DNJ 2:25-17893) (Watral, Diana) (Entered: 11/24/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001523341?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-24T00:00:00-08:00</updated></entry><entry><title>Entry #367 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-367" rel="alternate" /><published>2025-11-21T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-367</id><summary type="html">***TEXT ONLY NOTICE******A PROOF OF SERVICE IS REQUIRED FOR ALL FILINGS***NOTICE OF FILING OF CTO AND PUBLICATION OF BRIEFING SCHEDULE (CTO-43) re: pldg. (1 in INS/1:25-cv-02376, 1 in KYW/3:25-cv-00733, 366 in MDL No. 3094, 1 in NJ/3:25-cv-17639) BRIEFING SCHEDULE IS SET AS FOLLOWS: Oppositions due on or before 12/1/2025.Attorneys must be registered to file in the JPML. Please visit our website for Registration Information. Signed by Clerk of the Panel James V. Ingold on 11/21/2025. Associated Cases: MDL No. 3094, INS/1:25-cv-02376, KYW/3:25-cv-00733, NJ/3:25-cv-17639 (CT) (Entered: 11/21/2025)</summary><link href="https://ecf.jpml.uscourts.gov/cgi-bin/show_case_doc?367,1674416,,," length="0" rel="enclosure" /><updated>2025-11-21T00:00:00-08:00</updated></entry><entry><title>Entry #366 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-366" rel="alternate" /><published>2025-11-21T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-366</id><summary type="html">CONDITIONAL TRANSFER ORDER FILED TODAY (CTO-43) - 3 action(s) Signed by Clerk of the Panel James V. Ingold on 11/21/2025. Associated Cases: MDL No. 3094, INS/1:25-cv-02376, KYW/3:25-cv-00733, NJ/3:25-cv-17639 (CT) (Entered: 11/21/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001523062?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-21T00:00:00-08:00</updated></entry><entry><title>Entry #365 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-365" rel="alternate" /><published>2025-11-21T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-365</id><summary type="html">CONDITIONAL TRANSFER ORDER FINALIZED (CTO-42) - 1 action(s) re: pldg. ( 360 in MDL No. 3094, 1 in NJ/3:25-cv-17338) Inasmuch as no objection is pending at this time, the stay is lifted. Signed by Clerk of the Panel James V. Ingold on 11/21/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17338 (CT) (Entered: 11/21/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001522959?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-21T00:00:00-08:00</updated></entry><entry><title>Entry #364 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-364" rel="alternate" /><published>2025-11-20T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-364</id><summary type="html">NOTICE OF POTENTIAL TAG-ALONG -- 2 Action(s) -- Filed by attorney Loren H. Brown, counsel for Defendants Novo Nordisk A/S and Novo Nordisk Inc. -- Kentucky Western District Court (3:25-cv-00733), Indiana Southern District Court (1:25-cv-02376) (Attachments: # 1 Schedule of Actions, # 2 Proof of Service, # 3 Complaint KYW/3:25-cv-00733, # 4 Complaint INS/1:25-cv-02376) (Brown, Loren) (Entered: 11/20/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001522943?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-20T00:00:00-08:00</updated></entry><entry><title>Entry #363 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-363" rel="alternate" /><published>2025-11-18T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-363</id><summary type="html">NOTICE OF POTENTIAL TAG-ALONG -- 1 Action(s) -- Filed by attorney Diana M. Watral, P.C., counsel for Defendants Eli Lilly and Company and Lilly USA, LLC -- New Jersey District Court (3:25-cv-17639) (Attachments: # 1 Schedule of Actions, # 2 Proof of Service, # 3 Complaint - 3:25-cv-17639) (Watral, Diana) Modified on 11/19/2025 (CT). EDITED OFFICE NUMBER FROM 2 TO 3. (Entered: 11/18/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001522634?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-18T00:00:00-08:00</updated></entry><entry><title>Entry #362 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-362" rel="alternate" /><published>2025-11-18T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-362</id><summary type="html">CONDITIONAL TRANSFER ORDER FINALIZED (CTO-41) - 2 action(s) re: pldg. ( 356 in MDL No. 3094, 1 in NJ/3:25-cv-17268, 1 in NJ/3:25-cv-17272) Inasmuch as no objection is pending at this time, the stay is lifted. Signed by Clerk of the Panel James V. Ingold on 11/18/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17268, NJ/3:25-cv-17272 (JW) (Main Document 362 replaced on 11/18/2025) (JW). (Entered: 11/18/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001522592?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-18T00:00:00-08:00</updated></entry><entry><title>Minute entry from 2025-11-14 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/IN-RE:-Glucagon-like-Peptide-1 Receptor-Agonists-(GLP-1-RAs)-Products-LiabilityLitigation-(MDL-No.-3094)/" rel="alternate" /><published>2025-11-14T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#minute-entry-446012620</id><summary type="html">XYZ CASES ENTERED -- 22 related action(s) originating in the transferee district. JPML notified on 10/29/25 - 11/7/25 via NEF. -- Pennsylvania Eastern District Court (2:25-cv-06140,2:25-cv-06172,2:25-cv-06175,2:25-cv-06199,2:25-cv-06196,2:25-cv-06204, 2:25-cv-06203,2:25-cv-06202,2:25-cv-06205,2:25-cv-06207,2:25-cv-06176,2:25-cv-06215, 2:25-cv-06209,2:25-cv-06210,2:25-cv-06212,2:25-cv-06255,2:25-cv-06264,2:25-cv-06272, 2:25-cv-06273,2:25-cv-06292,2:25-cv-06296,2:25-cv-06321) (CT) Modified on 11/14/2025 (CT). EDITED NUMBER OF ACTIONS AND REMOVED CASE 2:25-cv-16950</summary><updated>2025-11-14T00:00:00-08:00</updated></entry><entry><title>Entry #361 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-361" rel="alternate" /><published>2025-11-13T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-361</id><summary type="html">***TEXT ONLY NOTICE******A PROOF OF SERVICE IS REQUIRED FOR ALL FILINGS***NOTICE OF FILING OF CTO AND PUBLICATION OF BRIEFING SCHEDULE (CTO-42) re: pldg. ( 360 in MDL No. 3094, 1 in NJ/3:25-cv-17338) BRIEFING SCHEDULE IS SET AS FOLLOWS: Oppositions due on or before 11/20/2025.Attorneys must be registered to file in the JPML. Please visit our website for Registration Information. Signed by Clerk of the Panel James V. Ingold on 11/13/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17338 (CT) (Entered: 11/13/2025)</summary><link href="https://ecf.jpml.uscourts.gov/cgi-bin/show_case_doc?361,1674416,,," length="0" rel="enclosure" /><updated>2025-11-13T00:00:00-08:00</updated></entry><entry><title>Entry #360 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-360" rel="alternate" /><published>2025-11-13T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-360</id><summary type="html">CONDITIONAL TRANSFER ORDER FILED TODAY (CTO-42) - 1 action(s) Signed by Clerk of the Panel James V. Ingold on 11/13/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17338 (CT) (Entered: 11/13/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001522074?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-13T00:00:00-08:00</updated></entry><entry><title>Entry #359 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-359" rel="alternate" /><published>2025-11-13T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-359</id><summary type="html">CONDITIONAL TRANSFER ORDER FINALIZED (CTO-40) - 3 action(s) re: pldg. ( 352 in MDL No. 3094, 1 in NJ/3:25-cv-17110, 1 in NJ/3:25-cv-17113, 1 in NJ/3:25-cv-17114) Inasmuch as no objection is pending at this time, the stay is lifted. Signed by Clerk of the Panel James V. Ingold on 11/13/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17110, NJ/3:25-cv-17113, NJ/3:25-cv-17114 (CT) (Entered: 11/13/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001522021?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-13T00:00:00-08:00</updated></entry><entry><title>Entry #358 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-358" rel="alternate" /><published>2025-11-10T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-358</id><summary type="html">NOTICE OF POTENTIAL TAG-ALONG -- 1 Action(s) -- Filed by attorney Diana M. Watral, P.C., counsel for Defendants Eli Lilly and Company and Lilly USA, LLC -- New Jersey District Court (3:25-cv-17338) (Attachments: # 1 Schedule of Actions, # 2 Proof of Service, # 3 DNJ 3:25-cv-17338) (Watral, Diana) (Entered: 11/10/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001521692?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-10T00:00:00-08:00</updated></entry><entry><title>Entry #357 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-357" rel="alternate" /><published>2025-11-10T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-357</id><summary type="html">***TEXT ONLY NOTICE******A PROOF OF SERVICE IS REQUIRED FOR ALL FILINGS***NOTICE OF FILING OF CTO AND PUBLICATION OF BRIEFING SCHEDULE (CTO-41) re: pldg. ( 356 in MDL No. 3094, 1 in NJ/3:25-cv-17268, 1 in NJ/3:25-cv-17272) BRIEFING SCHEDULE IS SET AS FOLLOWS: Oppositions due on or before 11/17/2025.Attorneys must be registered to file in the JPML. Please visit our website for Registration Information. Signed by Clerk of the Panel James V. Ingold on 11/10/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17268, NJ/3:25-cv-17272 (CT) (Entered: 11/10/2025)</summary><link href="https://ecf.jpml.uscourts.gov/cgi-bin/show_case_doc?357,1674416,,," length="0" rel="enclosure" /><updated>2025-11-10T00:00:00-08:00</updated></entry><entry><title>Entry #356 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-356" rel="alternate" /><published>2025-11-10T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-356</id><summary type="html">CONDITIONAL TRANSFER ORDER FILED TODAY (CTO-41) - 2 action(s) Signed by Clerk of the Panel James V. Ingold on 11/10/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17268, NJ/3:25-cv-17272 (CT) (Entered: 11/10/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001521507?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-10T00:00:00-08:00</updated></entry><entry><title>Entry #355 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-355" rel="alternate" /><published>2025-11-06T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-355</id><summary type="html">NOTICE OF POTENTIAL TAG-ALONG -- 2 Action(s) -- Filed by attorney Diana M. Watral, P.C., counsel for Defendants Eli Lilly and Company and Lilly USA, LLC -- New Jersey District Court (2:25-cv-17272,2:25-cv-17268) (Attachments: # 1 Schedule of Actions, # 2 Proof of Service, # 3 Complaint - 2:25-cv-17272, # 4 Complaint 2:25-cv-17268) (Watral, Diana) (Entered: 11/06/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001521140?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-06T00:00:00-08:00</updated></entry><entry><title>Entry #354 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-354" rel="alternate" /><published>2025-11-06T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-354</id><summary type="html">CONDITIONAL TRANSFER ORDER FINALIZED (CTO-39) - 1 action(s) re: pldg. ( 348 in MDL No. 3094, 1 in NJ/3:25-cv-16950) Inasmuch as no objection is pending at this time, the stay is lifted. Signed by Clerk of the Panel James V. Ingold on 11/6/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-16950 (CT) (Entered: 11/06/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001520993?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-06T00:00:00-08:00</updated></entry><entry><title>Minute entry from 2025-11-05 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/IN-RE:-Glucagon-like-Peptide-1 Receptor-Agonists-(GLP-1-RAs)-Products-LiabilityLitigation-(MDL-No.-3094)/" rel="alternate" /><published>2025-11-05T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#minute-entry-446012594</id><summary type="html">XYZ CASES ENTERED -- 1 related action(s) originating in the transferee district. JPML notified on 10/14/25 via NEF. -- Pennsylvania Eastern District Court (2:25-cv-05856) (DLD)</summary><updated>2025-11-05T00:00:00-08:00</updated></entry><entry><title>Entry #353 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-353" rel="alternate" /><published>2025-11-05T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-353</id><summary type="html">***TEXT ONLY NOTICE******A PROOF OF SERVICE IS REQUIRED FOR ALL FILINGS***NOTICE OF FILING OF CTO AND PUBLICATION OF BRIEFING SCHEDULE (CTO-40) re: pldg. ( 352 in MDL No. 3094, 1 in NJ/3:25-cv-17110, 1 in NJ/3:25-cv-17113, 1 in NJ/3:25-cv-17114) BRIEFING SCHEDULE IS SET AS FOLLOWS: Oppositions due on or before 11/12/2025.Attorneys must be registered to file in the JPML. Please visit our website for Registration Information. Signed by Clerk of the Panel James V. Ingold on 11/5/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17110, NJ/3:25-cv-17113, NJ/3:25-cv-17114 (CT) (Entered: 11/05/2025)</summary><link href="https://ecf.jpml.uscourts.gov/cgi-bin/show_case_doc?353,1674416,,," length="0" rel="enclosure" /><updated>2025-11-05T00:00:00-08:00</updated></entry><entry><title>Entry #352 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-352" rel="alternate" /><published>2025-11-05T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-352</id><summary type="html">CONDITIONAL TRANSFER ORDER FILED TODAY (CTO-40) - 3 action(s) Signed by Clerk of the Panel James V. Ingold on 11/5/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-17110, NJ/3:25-cv-17113, NJ/3:25-cv-17114 (CT) (Entered: 11/05/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001520803?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-05T00:00:00-08:00</updated></entry><entry><title>Entry #351 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-351" rel="alternate" /><published>2025-11-03T00:00:00-08:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-351</id><summary type="html">NOTICE OF POTENTIAL TAG-ALONG -- 3 Action(s) -- Filed by attorney Diana M. Watral, P.C., counsel for Defendants Eli Lilly and Company and Lilly USA, LLC -- New Jersey District Court (3:25-cv-17110,3:25-cv-17113,3:25-cv-17114) (Attachments: # 1 Schedule of Actions, # 2 Proof of Service, # 3 Complaint - 3:25-cv-17110, # 4 Complaint - 3:25-cv-17113, # 5 Complaint - 3:25-cv-17114) (Watral, Diana) (Entered: 11/03/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001520538?caseid=1674416" length="0" rel="enclosure" /><updated>2025-11-03T00:00:00-08:00</updated></entry><entry><title>Entry #350 in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094</title><link href="https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-350" rel="alternate" /><published>2025-10-31T00:00:00-07:00</published><id>https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/?order_by=desc#entry-350</id><summary type="html">CONDITIONAL TRANSFER ORDER FINALIZED (CTO-38) - 1 action(s) re: pldg. ( 345 in MDL No. 3094, 1 in NJ/3:25-cv-16724) Inasmuch as no objection is pending at this time, the stay is lifted. Signed by Clerk of the Panel James V. Ingold on 10/31/2025. Associated Cases: MDL No. 3094, NJ/3:25-cv-16724 (CT) (Entered: 10/31/2025)</summary><link href="https://ecf.jpml.uscourts.gov/doc1/85001520155?caseid=1674416" length="0" rel="enclosure" /><updated>2025-10-31T00:00:00-07:00</updated></entry></feed>